Global Depression Screening Market Opportunities and Forecast 2020-2027

1 Report Prologue 12

2 Market Introduction 16

• 2.1 Scope of Study 16
• 2.2 Research Objective 16
• 2.3 Assumptions & Limitations 16
  • 2.3.1 Assumptions 16
  • 2.3.2 Limitations 16

3 Research Methodology 17

• 3.1 Primary Research Methodology 18
• 3.2 Secondary Research Methodology 19
• 3.3 Market Share Analysis 20
• 3.4 Trade Analysis 20
• 3.5 Market Pricing Approach 20

4 Market Dynamics 21

• 4.1 Introduction 21
• 4.2 Drivers 22
  • 4.2.1 Emergence of digital health technologies in mental health (Impact weightage-45%) 22
  • 4.2.2 Growing prevalence of mental disorders around the globe (Impact weightage-30%) 23
  • 4.2.3 New focus areas in the care continuum are prevention and recovery (Impact weightage-25%) 24
• 4.3 Restraints 25
  • 4.3.1 Low public awareness of mental disorders and treatments in emerging nations (Impact weightage-55%) 25
  • 4.3.2 Cultural Stigma preventing the market growth (Impact weightage-45%) 26

5 Market Factor Analysis 27

• 5.1 Porter’s Five Forces Model 27
  • 5.1.1 Bargaining Power of Suppliers 28
  • 5.1.2 Bargaining Power of Buyers 28
  • 5.1.3 Threat of New Entrants 28
  • 5.1.4 Threat of Substitutes 28
  • 5.1.5 Intensity of Rivalry 28
• 5.2 Value Chain Analysis 29

6 Global Depression Screening Market, By Disease Type 30

• 6.1 Introduction 30
• 6.2 Anxiety 32
• 6.3 Mood Disorders 32
• 6.4 Depression 33
• 6.5 Bipolar Disorders 33
• 6.6 Psychotic Disorders 34
• 6.7 Eating Disorders 34

7 Global Depression Screening Market, By Diagnosis 35

• 7.1 Introduction 35
• 7.2 Psychological Test 36
• 7.3 Lab Tests 37
• 7.4 Depression Screening Tests 37

8 Global Depression Screening Market, By Treatment 38

• 8.1 Introduction 38
• 8.2 Medication 40
• 8.3 Brain-Stimulation Treatments 40
• 8.4 Substance Abuse Treatment 41

9 Global Depression Screening Market, By End User 42

• 9.1 Introduction 42
• 9.2 Hospitals & Clinics 43
• 9.3 Medical Research Centers 43
• 9.4 Academic Institutes 44

10 Global Depression Screening Market, By Region 45

• 10.1 Introduction 45
• 10.2 Americas 46
  • 10.2.1 U.S. 49
  • 10.2.2 Canada 51
  • 10.2.3 South America 53
• 10.3 Europe 55
  • 10.3.1 Germany 58
  • 10.3.2 France 60
  • 10.3.3 UK 62
  • 10.3.4 Italy 64
  • 10.3.5 Spain 66
  • 10.3.6 Rest of Western Europe 68
  • 10.3.7 Eastern Europe 70
• 10.4 Asia Pacific 72
  • 10.4.1 Japan 75
  • 10.4.2 China 77
  • 10.4.3 India 79
  • 10.4.4 Australia 81
  • 10.4.5 Republic of Korea 83
  • 10.4.6 Rest of Asia Pacific 85
• 10.5 Middle East & Africa 87
  • 10.5.1 Middle East 90
  • 10.5.2 Africa 92

11 Company Share Analysis 94

12 Company Profiles: Top 7 Players 95

• 12.1 Allergan 95
  • 12.1.1 Company Overview 95
  • 12.1.2 Financials 95
  • 12.1.3 Products 95
  • 12.1.4 Strategy 95
  • 12.1.5 Key Developments 95
• 12.2 Eli Lilly 96
  • 12.2.1 Company Overview 96
  • 12.2.2 Financials 96
  • 12.2.3 Products 96
  • 12.2.4 Strategy 96
  • 12.2.5 Key Developments 96
• 12.3 Novartis AG. 97
  • 12.3.1 Company Overview 97
  • 12.3.2 Financials 97
  • 12.3.3 Products 97
  • 12.3.4 Strategy 97
  • 12.3.5 Key Developments 97
• 12.4 Alkermes 98
  • 12.4.1 Company Overview 98
  • 12.4.2 Financials 98
  • 12.4.3 Products 98
  • 12.4.4 Strategy 98
  • 12.4.5 Key Developments 98
• 12.5 Bristol-Myers Squibb Company 99
  • 12.5.1 Company Overview 99
  • 12.5.2 Financials 99
  • 12.5.3 Products 99
  • 12.5.4 Strategy 99
  • 12.5.5 Key Developments 99
• 12.6 Pfizer 100
  • 12.6.1 Company Overview 100
  • 12.6.2 Financials 100
  • 12.6.3 Products 100
  • 12.6.4 Strategy 100
  • 12.6.5 Key Developments 100
• 12.7 AstraZeneca 101
  • 12.7.1 Company Overview 101
  • 12.7.2 Financials 101
  • 12.7.3 Products 101
  • 12.7.4 Srategy 101
  • 12.7.5 Key Developments 101